Cessatech annonces the issuance of its first US patent covering CT001

Report this content

Copenhagen, Denmark, 02 November 2021 – Cessatech A/S (“Cessatech” or the “Company”) announces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799 to the Company, which is directed to a storage stable pre-filled and ready to use nasal spray device comprising sufentanil and ketamine and a method of treating or preventing pain in a child by use of said device.

CT001 is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful. CT001 has a fast onset and is easy to use. Its composition includes a fixed combination of the two well-known analgesics, sufentanil and ketamine, which are already approved treatments for injection in adults. The patent is a milestone in the development activities and will be an important element in the activities going forward.

Cessatech continues to develop its intellectual property portfolio for CT001, its lead asset, and the issuance of this first US patent is an important milestone in establishing a solid patent protection for CT001

Comment from Jes Trygved, CEO of Cessatech
We are very pleased with the issuance of the US patent which constitutes an important element and foundation for our further activities and considerations for the US, one of the most important markets, also when it comes to children needing acute pain treatment . We have a number of related activities ongoing for the US and hope to initiate some of these in 2022. We continue to work hard to get CT001 available for the treatment of acute pain in children. 

This disclosure contains information that Cessatech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-11-2021 18:00 CET.

For more information about Cessatech, please contact:

Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com

About Cessatech A/S
Cessatech’s business model offers unique, scalable economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile. The drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a focused development plan can be applied for documenting good effect in children. Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures.